BioTime Co-CEO Adi Mohanty to Participate in Panel Discussion at the Cell & Gene Therapy CEO Forum

ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology
company focused on developing and commercializing products addressing
degenerative diseases, today announced that Co-Chief Executive Officer
Adi Mohanty will participate in a panel discussion at Cell
& Gene Therapy CEO
on Monday, September 25,2017 in

The panel, titled “Financing Innovation: Attracting Investment” is at
2:00pm ET/11:00am PT. The discussion will be moderated by Rich Daly,
Chairman and CEO of Neuralstem. Panelists include Mark Barrett,
Entrepreneur-in-Residence, Frazier Healthcare Partners, David Grainger,
Ph.D., CEO of Methuselah
and Partner at Medicxi,
and Nora
, Director, Portfolio Management & Strategic Operations at the National
Center for Advancing Translational Sciences
, National Institutes of

Cell & Gene Therapy CEO is an off-the-record networking forum that
brings together CEOs and decision makers in cell therapy, gene therapy,
and regenerative medicine. Intimate discussion panels, keynotes and
fireside chats feature thought leaders debating business model
efficiencies, financing, regulatory issues, market access and
reimbursement, novel partnerships, manufacturing, and delivery
challenges. Healthcare investors and leading researchers also

About BioTime

BioTime is a clinical-stage biotechnology company focused on developing
and commercializing products addressing degenerative diseases. The
Company’s current clinical programs are targeting three primary sectors,
aesthetics, ophthalmology and cell/drug delivery. Its clinical programs
are based on two platform technologies: pluripotent cells and cell/drug
delivery. The foundation of BioTime’s core therapeutic technology
platform is pluripotent cells that are capable of becoming any of the
cell types in the human body. The foundation of the Company’s cell
delivery platform is its HyStem® cell and drug delivery matrix
technology. BioTime also has significant equity holdings in two publicly
traded companies, Asterias Biotherapeutics, Inc. and OncoCyte
Corporation, and one private company, AgeX Therapeutics.

BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit or
connect with the company on TwitterLinkedInFacebookYouTube,
and Google+.

To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list:


Investor Contact:
David Nakasone 510-871-4188
Contact for BioTime
Gotham Communications, LLC
Bill Douglass,